For type 2 diabetes mellitus. ANDA 78596, held by Amneal Pharms Ny. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 78596 (Metformin Hydrochloride), held by Amneal Pharms Ny, was first approved by FDA on Jan 3, 2008, with 6 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 3, 2008 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 39Labeling · Standard review | Approved | None posted |
| Jul 30, 2026 | Supplement 33Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 19, 2012 | Supplement 7Manufacturing | Approved | None posted |
| May 26, 2010 | Supplement 4Labeling | Approved | None posted |
| Jan 3, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters